The Latest Breaking News from Numinus

Numinus Updates On New Acquisition’s Integration And Provides Client Financing Options

The medical benefits of psychedelic drugs have gone from Age of Aquarius punchline to solid science, but the startups racing to market might still be getting ahead of themselves.

Numinus Wellness Inc.

A longstanding commitment of Numinus Wellness Inc. (OTC: NUMIF) to collaborate with Health Canada to help shape protocols for the Special Access Program appears to be paying dividends.

Numinus Wellness Inc (OTCQB: NUMIF) has been approved to use psilocybin-assisted therapy through Health Canada’s Special Access Program (SAP), marking the first instance in which Numinus will provide this treatment outside of a clinical trial.

June 8, 2022 marks a turning point for both Numinus (OTCQX: NUMIF) and Novamind (OTCQB: NVMDF).

In a year where M&A activity is expected to ratchet-up in 2022, Numinus Wellness Inc. (OTC: NUMIF) is among the first to take action.

Numinus Wellness Inc. (TSX:NUMI)(OTCQX:NUMIF) and Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) have entered into a definitive arrangement agreement pursuant to which Numinus will acquire all of the issued and outstanding common shares of Novamind in an all-share transaction, by way of a court-approved plan of arrangement, for total consideration of approximately CA$26.2 million…

Numinus Wellness Inc. (OTCQX:NUMIF), announced that clinical trial MAPPUSX has gotten underway with the enrolling and dosing of the first trial volunteer in Canada. MAPPUSX, which stands for "A multi-site open-label extension study of MDMA-assisted psychotherapy for PTSD”, is sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS) and organized by…